After 2 Trillion Won Share Buyback, Executives Sell Shares: Conflicting Signals from Bio Companies

UNITED THERAPEUTICS Corp (UTHR) announced on March 9, 2026 that its board approved a new share repurchase program of up to $2 billion (approximately KRW 2.7 trillion) over the next year, and that $1.5 billion (about KRW 2 trillion) would be executed immediately under an accelerated share repurchase agreement with Citibank. Then, on March 20 and 23, the CEO and CFO each exercised stock options and, under 10b5-1 trading plans, sold ordinary shares worth tens of millions of dollars (billions of Korean won) in the open market to realize some gains; company filings show both executives still retain substantial remaining holdings.

Recently, the company’s stock jumped more than 10% in a single day after it released positive results from the TETON-1 Phase 3 trial of inhaled Tyvaso in patients with idiopathic pulmonary fibrosis, and just prior to that, it exceeded market expectations on earnings per share in its latest report—prompting brokerages to raise their price targets and driving further upside.

United Therapeutics, founded in 1996, is a U.S. biotech company focused on developing therapies for rare pulmonary diseases—such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis—as well as artificial organs for transplantation and xenotransplantation technologies. Building on revenues from existing PAH treatments like Tyvaso, Remodulin and Orenitram, the company is expanding its inhaled and oral formulations and commercializing organ-manufacturing technologies, thereby strengthening its position in the pulmonary-disease and transplant healthcare markets.